Physician profile
Victor Aurel Neamtu
NPI 1508009754
$2,467.20
in general payments reported to CMS, 2019-2025
15 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $99.73 · 2021: $211 · 2022: $203 · 2023: $515 · 2024: $501 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.64 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $506.84 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $371.09 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $329.22 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $291.76 | 2022-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $275.55 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $252.70 | 2023-2025 | Syfovre |
| Abbvie INC. | $171.54 | 2023-2025 | |
| Biogen, INC. | $99.53 | 2022-2023 | |
| Allergan, INC. | $78.82 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $48.08 | 2025 | Iluvien, Purified Cortrophin Gel |
| Eyepoint US, INC. | $23.17 | 2019 | |
| Coopervision INC. | $18.90 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Neamtu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.